Rhabdomyolysis Risk: The Dangers of Tribulus Terrestris, an Over-the-Counter Supplement

Ross Huff; Katarzyna Karpinska-Leydier; Gautam Maddineni; Dustin Begosh-Mayne

doi:10.12659/AJCR.943492

16 July 2024 : Case report USA

Rhabdomyolysis Risk: The Dangers of Tribulus Terrestris, an Over-the-Counter Supplement

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Rare disease, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons

Ross Huff^12AEF*, Katarzyna Karpinska-Leydier^12EF, Gautam Maddineni^12EF, Dustin Begosh-Mayne^12EF

DOI: 10.12659/AJCR.943492

Am J Case Rep 2024; 25:e943492

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 1. Trend of the creatinine phosphokinase levels from admission at day 1 up until discharge on day 6. Levels peaked on day 4 at 11 972U/L, then rapidly declined.

Back to the Article

Rhabdomyolysis Risk: The Dangers of Tribulus Terrestris, an Over-the-Counter Supplement

Your Privacy